San Diego, USA, 2019-03-04 - NBE-Therapeutics invited to present at Terrapinn's Americas Antibody Congress
Roger Beerli, CSO of NBE-Therapeutics, is invited to provide an update on NBE-Therapeutics' ADC development activities at Terrapinn's Americas Antibody Congress, which is part of the 2019 Festival of Biologics USA
NBE-Therapeutics is invited for a presentation at Terrapinn's 2019 Festival of Biologics USA, which includes the Americas Antibody Congress, the World Immunotherapy Congress USA and the World Biosimilar Congress USA. Roger's presentation will take place in the "Armed antibodies" stream of the Americas Antibody Congress on Monday, March 4, 3:00 p.m. and is entitled "Preclinical Validation of a Site-specifically Conjugated, ROR1-specific Anthracycline-ADC with Potent Immune-stimulatory Functions". In his presentation, Roger will present data on the strong immune-stimulatory function of NBE's iADCs that can trigger a long-lasting anti-tumor immunity in syngeneic mouse tumor models.
Recent news feed
RSS feed from: